Clinical breast cancer最新文献

{"title":"Is Immediate Breast Reconstruction an Option for Elderly Women? A Comparative Study Between Elderly and Younger Population.","authors":"Julie Marcadet, Caroline Bouche, Carlo Arellano, Elodie Gauroy, Mony Ung, Eva Jouve, Gabrielle Selmes, Marc Soule-Tholy, Thomas Meresse, Carole Massabeau, Ana Cavillon, Charlotte Vaysse","doi":"10.1016/j.clbc.2025.01.001","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.01.001","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the incidence of postoperative complications (POC) in elderly patients (EP) compared to younger patients (YP) following immediate breast reconstruction (IBR) after total mastectomy (TM).</p><p><strong>Methods: </strong>This retrospective study included patients treated at the Institut Universitaire of Cancer of Toulouse-Oncopole (IUCT-O) between January 2014 and May 2022. The primary outcome was the incidence of POC within 30 days postoperatively. Secondary outcomes included the delay before initiation of adjuvant treatments and re-hospitalization rates.</p><p><strong>Results: </strong>Elderly patients had a significantly higher rate of POC compared to younger patients, affecting 27.9% of EP and only 14.8% of YP. However, the severity of complications does not differ significantly between YP and EP (69.1% of major POC for YP and 64.7% for EP, P = .6680). Rates of re-hospitalization within 30 days between the 2 groups are similar (67.3% for YP and 61.8% for EP, P = .5962). Most importantly, these complications are not responsible for a delay in initiating adjuvant treatment compared with the younger population. Age ≥ 70 years and obesity (BMI ≥ 30) were identified as independent risk factors for POC.</p><p><strong>Conclusion: </strong>Despite a higher rate of POC, immediate breast reconstruction can be considered for elderly patients, but these patients should be carefully selected and assessed preoperatively to limit the risk of POC.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Preoperative Prediction Model Based on Spectral CT to Evaluate Axillary Lymph Node With Macrometastases in Clinical T1/2N0 Invasive Breast Cancer","authors":"Fang Zeng ,&nbsp;Weifeng Cai ,&nbsp;Lin Lin ,&nbsp;Cong Chen ,&nbsp;Xiaoxue Tang ,&nbsp;Zheting Yang ,&nbsp;Yilin Chen ,&nbsp;Lihong Chen ,&nbsp;Lili Chen ,&nbsp;Jing Li ,&nbsp;Suping Chen ,&nbsp;Chuang Wang ,&nbsp;Yunjing Xue","doi":"10.1016/j.clbc.2024.06.010","DOIUrl":"10.1016/j.clbc.2024.06.010","url":null,"abstract":"<div><h3>Objectives</h3><div>To develop a prediction model based on spectral computed tomography<span> (CT) to evaluate axillary lymph node (ALN) with macrometastases in clinical T1/2N0 invasive breast cancer.</span></div></div><div><h3>Methods</h3><div>A total of 217 clinical T1/2N0 invasive breast cancer patients who underwent spectral CT scans were retrospectively enrolled and categorized into a training cohort (n = 151) and validation cohort (n = 66). These patients were classified into ALN nonmacrometastases (stage pN0 or pN0 [i+] or pN1mi) and ALN macrometastases (stage pN1-3) subgroups. The morphologic criteria and quantitative spectral CT parameters of the most suspicious ALN were measured and compared. Least absolute shrinkage and selection operator (Lasso) was used to screen predictive indicators to build a logistic model. The receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used to evaluate the models.</div></div><div><h3>Results</h3><div><span>The combined arterial-venous phase spectral CT model yielded the best diagnostic performance in discrimination of ALN nonmacrometastases and ALN macrometastases with the highest AUC (0.963 in the training cohort and 0.945 in validation cohorts). Among single phase spectral CT models, the venous phase spectral CT model showed the best performance (AUC = 0.960 in the training cohort and 0.940 in validation cohorts). There was no significant difference in AUCs among the 3 models (DeLong test, </span><em>P</em> &gt; .05 for each comparison).</div></div><div><h3>Conclusion</h3><div>A Lasso-logistic model that combined morphologic features and quantitative spectral CT parameters based on contrast-enhanced spectral imaging potentially be used as a noninvasive tool for individual preoperative prediction of ALN status in clinical T1/2N0 invasive breast cancers.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e10-e21.e1"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141574921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor of Clinical Breast Cancer, on “Omitting Axillary Lymph Node Dissection is Associated With an Increased Risk of Regional Recurrence in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials” Conducted by Jorge Henrique Cardoso and Collaborators and Published in Clinical Breast Cancer doi.org/10.1016/j.clbc.2024.07.011","authors":"André Mattar ,&nbsp;Francisco Pimentel Cavalcante ,&nbsp;Marcelo Antonini ,&nbsp;Felipe Zerwes ,&nbsp;Eduardo de Camargo Millen ,&nbsp;Fabrício Palermo Brenelli ,&nbsp;Antônio Luiz Frasson ,&nbsp;Lucas Miyake Okumura","doi":"10.1016/j.clbc.2024.08.014","DOIUrl":"10.1016/j.clbc.2024.08.014","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e96-e98"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Breast Cancer Survival Prognosis Through Omic and Non-Omic Data Integration","authors":"Kishaanth Sathyamoorthi,&nbsp;Abishek VP,&nbsp;Lokeswari Y Venkataramana,&nbsp;Venkata Vara Prasad D","doi":"10.1016/j.clbc.2024.08.009","DOIUrl":"10.1016/j.clbc.2024.08.009","url":null,"abstract":"<div><h3>Background and Objective</h3><div>Cancer, the second leading cause of death globally, claimed 685,000 lives among 2.3 million women affected by breast cancer in 2020. Cancer prognosis plays a pivotal role in tailoring treatments and assessing efficacy, emphasizing the need for a comprehensive understanding. The goal is to develop predictive model capable of accurately predicting patient outcomes and guiding personalized treatment strategies, thereby advancing precision medicine in breast cancer care.</div></div><div><h3>Methods</h3><div>This project addresses limitations in current cancer prognosis models by integrating omics and non-omics data. While existing models often neglect crucial omics data like DNA methylation and miRNA, the method utilizes the TCGA dataset to incorporate these data types along with others. Employing mRMR feature selection and CNN models for each type of data for feature extraction, features are stacked and a Random Forest classifier is employed for final prognosis.</div></div><div><h3>Result</h3><div>The proposed method is applied to the dataset to predict whether the patient is a long-time or a short-time survivor. This strategy showcases excellent performance, with an AUC value of 0.873, precision at 0.881, and sensitivity reaching 0.943. With an accuracy rate of 0.861, signaling an improvement of 11.96% compared to prior studies.</div></div><div><h3>Conclusion</h3><div>In conclusion, integrating diverse data with advanced machine learning holds promise for improving breast cancer prognosis. Addressing model limitations and leveraging comprehensive datasets can enhance accuracy, paving the way for better patient care. Further refinement offers potential for significant advancements in cancer prognosis and treatment strategies.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 27-37"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding the Article “The Impact of COVID-19 on Breast Cancer Care: A Qualitative Analysis of Surgeons’ Perspectives”","authors":"Akshaya viswanathan,&nbsp;Pitchaipillai Sankar Ganesh,&nbsp;Naji Naseef Pathoor,&nbsp;Rajesh Kanna Gopal","doi":"10.1016/j.clbc.2024.10.015","DOIUrl":"10.1016/j.clbc.2024.10.015","url":null,"abstract":"<div><div>The COVID-19 pandemic exposed significant challenges in breast cancer care including healthcare inequities, limited access to surgeries, and difficulties in delivering virtual care. This letter builds upon the findings from the article “The Impact of COVID-19 on Breast Cancer Care” and proposes innovative solutions to address these challenges. Key suggestions include the use of AI-powered digital platforms for remote monitoring, robotic-assisted surgery for enhanced precision, mobile health applications for marginalized populations, and 3D printing for personalized breast reconstruction. Additionally, wearable health devices, nanotechnology for targeted drug delivery, and blockchain for secure medical data sharing are proposed to further improve the future of breast cancer care. These innovations offer practical approaches to overcoming the obstacles highlighted during the pandemic and aim to create a more equitable and efficient healthcare system.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e100-e102"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of Radiomics and Immune-Related Genes Signatures for Predicting Axillary Lymph Node Metastasis in Breast Cancer","authors":"Xue Li ,&nbsp;Lifeng Yang ,&nbsp;Fa Jiang ,&nbsp;Xiong Jiao","doi":"10.1016/j.clbc.2024.06.014","DOIUrl":"10.1016/j.clbc.2024.06.014","url":null,"abstract":"<div><h3>Background</h3><div><span>To develop a radiogenomics nomogram for predicting </span>axillary lymph node<span> (ALN) metastasis in breast cancer and reveal underlying associations between radiomics features and biological pathways.</span></div></div><div><h3>Materials and methods</h3><div>This study included 1062 breast cancer patients, 90 patients with both DCE-MRI and gene expression data<span>. The optimal immune-related genes and radiomics features associated with ALN metastasis were firstly calculated, and corresponding feature signatures were constructed to further validate their performances in predicting ALN metastasis. The radiogenomics nomogram for predicting the risk of ALN metastasis was established by integrating radiomics signature, immune-related genes (IRG) signature, and critical clinicopathological factors. Gene modules associated with key radiomics features were identified by weighted gene co-expression network analysis (WGCNA) and submitted to functional enrichment analysis. Gene set variation analysis (GSVA) and correlation analysis were performed to investigate the associations between radiomics features and biological pathways.</span></div></div><div><h3>Results</h3><div><span><span>The radiogenomics nomogram showed promising predictive power for predicting ALN metastasis, with AUCs of 0.973 and 0.928 in the training and testing groups, respectively. WGCNA and functional enrichment analysis revealed that gene modules associated with key radiomics features were mainly enriched in breast cancer metastasis-related pathways, such as focal adhesion, ECM-receptor interaction, and </span>cell adhesion molecules. GSVA also identified pathway activities associated with radiomics features such as </span>glycogen synthesis, integration of energy metabolism.</div></div><div><h3>Conclusion</h3><div>The radiogenomics nomogram can serve as an effective tool to predict the risk of ALN metastasis. This study provides further evidence that radiomics phenotypes may be driven by biological pathways related to breast cancer metastasis.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e40-e47.e4"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast","authors":"Chiara M. Ciniselli ,&nbsp;Paolo Verderio ,&nbsp;Paolo Baili ,&nbsp;Milena Sant ,&nbsp;Sara Pizzamiglio ,&nbsp;Valeria Duroni ,&nbsp;Filippo G. de Braud ,&nbsp;Secondo Folli ,&nbsp;Gianfranco Scaperrotta ,&nbsp;Maria C. De Santis ,&nbsp;Giovanni Apolone ,&nbsp;Cinzia De Marco ,&nbsp;Andrea Vingiani ,&nbsp;Vera Cappelletti ,&nbsp;Giancarlo Pruneri ,&nbsp;Serena Di Cosimo","doi":"10.1016/j.clbc.2024.08.002","DOIUrl":"10.1016/j.clbc.2024.08.002","url":null,"abstract":"<div><h3>Background</h3><div>Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer, with 5-10% of cases progressing into invasive disease. Herein, we investigated the association between HER2-low and clinico-pathological characteristics in DCIS and subsequent ipsilateral loco-regional relapse (LRR).</div></div><div><h3>Materials and methods</h3><div>We accessed our prospectively maintained institutional database. HER2 status was determined by immunohistochemistry and classified as null (score 0), over-expressed (3+), and low (1+ or 2+); in situ hybridization was not considered since it is not used for routine DCIS diagnostics.</div></div><div><h3>Results</h3><div>Among 375 patients with DCIS, median age was 54 (27-88) years, with a primary tumor size &lt; 2.5 cm in 63%, grade III in 33%, and positive hormone receptor status (HR) in 81% of cases; 71% underwent breast-conserving surgery, 34% received adjuvant endocrine and 39% radiotherapy. A total of 197 (52%) had tumors with low HER2 expression, which resulted significantly associated with grade I/II (<em>P</em> &lt; .001), Ki67&lt; 20% (<em>P</em> &lt; .001), and HR-positive status (<em>P</em> &lt; .001). HER2-low distribution varied from 19.61% and 50% in ER negative and ER-low (&lt;10%) to 60% and 69% in ER high (50%-95%) and very high tumors (&gt; 95%) (<em>P</em> &lt; .001). After a median 39-month follow-up (IQR 16-65), cumulative incidences of LRR was 0.054. Among 17 patients with paired primary tumor and LRR, 5 had discordant HER2 status, with an even distribution of increased and decreased HER2 expression.</div></div><div><h3>Conclusions</h3><div>Low HER2 expression in DCIS is associated with features of reduced aggressiveness. Importantly, changes in HER2 expression may occur prompting retesting in recurrent cases, in line with observations in invasive breast cancer.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e79-e85.e1"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Hereditary Genetic Testing in Patients with Triple Negative Breast Cancer","authors":"Shruti Gupta ,&nbsp;Jade E. Jones ,&nbsp;Demetria Smith-Graziani","doi":"10.1016/j.clbc.2024.09.018","DOIUrl":"10.1016/j.clbc.2024.09.018","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately affects younger females, non-Hispanic Black women, Hispanic women, and women with the <em>BRCA1</em> gene mutation. Hereditary genetic testing is particularly important in this population to assess preventative and treatment strategies, however access to genetic testing is variable. A qualitative review was performed to evaluate barriers to genetic testing for patients with TNBC. Mutations common in breast cancer are reviewed along with updated guidelines on management strategies, including the ability to include <em>PARP</em> inhibitors as a treatment strategy. Barriers to genetic testing are multifactorial, with non-Hispanic Black women being tested less often than other groups. The disparity is even further represented by the limited number of non-Hispanic Black patients with TNBC who receive risk-reducing surgery or targeted systemic therapy. Eliminating barriers to genetic testing can allow us to support guideline-directed care for patients with TNBC at higher risk for genetic mutations.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 12-18.e1"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Features and Digital Imaging Analysis of HER2 Protein in Breast Carcinomas With Different HER2 Fluorescence in Situ Hybridization Patterns","authors":"Aidan C. Li ,&nbsp;Scott Hammond ,&nbsp;Debra Crosby ,&nbsp;Zaibo Li ,&nbsp;Anil V. Parwani","doi":"10.1016/j.clbc.2024.10.004","DOIUrl":"10.1016/j.clbc.2024.10.004","url":null,"abstract":"<div><h3>Background</h3><div>HER2-targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer (BC), which represents 15% to 20% of all BC cases. HER2 status is assessed via immunohistochemistry (IHC) and/or in situ hybridization (ISH), dividing BCs into five groups (G1-G5).</div></div><div><h3>Patients and methods</h3><div>In a study of 2,702 primary BC cases, comprising 12.7% G1, 0.2% G2, 2.8% G3, 8.5% G4, and 75.9% G5, we analyzed clinicopathologic features and HER2 protein expression digitally for each ISH group.</div></div><div><h3>Results</h3><div>Notably, G5 cases had a higher proportion of lobular carcinoma (13.9%) compared to other groups. G3 cases showed the highest percentage of grade 3 tumors (56.9%), while G5 cases had the lowest (21.4%). Additionally, G5 cases had the highest rate of estrogen receptor (ER) positivity (84.6%), while G1-HC (high copy number) cases had the lowest (70.4%). Most G1-HC cases were HER2 IHC 3+ (76.1%), while most G5 cases were IHC 0/1+ (75.7%). IHC 2+ was most common in G1-LC (low copy number) and G3 cases (83.8% and 90.7%, respectively), with G4 cases predominantly IHC 2+ (56.3%) and IHC 1+ (30.1%). Discordant HER2 IHC and ISH results were observed in 12 cases (0.4%), including 7 G1-HC (2.3%), 4 G1-LC (10.8%), and 1 G5 case (0.1%). Digital quantification of HER2 IHC levels in all groups except G5 revealed that G1-HC tumors had the highest HER2 protein expression, followed by G3, with G4 showing the lowest.</div></div><div><h3>Conclusion</h3><div>These findings offer valuable insights into the clinicopathologic characteristics and future management for different HER2 ISH groups.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 38-45"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life Outcomes in Breast Cancer Patients Receiving Chemotherapy With or Without Radiation Therapy","authors":"Ryan T. Morse ,&nbsp;Nathan W. Bean ,&nbsp;Jacob Hall ,&nbsp;Allison Deal ,&nbsp;Kirsten A. Nyrop ,&nbsp;Yara Abdou ,&nbsp;Elizabeth C. Dees ,&nbsp;Emily M. Ray ,&nbsp;Trevor A. Jolly ,&nbsp;Katherine E. Reeder-Hayes ,&nbsp;Ellen Jones ,&nbsp;Gaorav P. Gupta ,&nbsp;Shekinah Elmore ,&nbsp;Hyman B. Muss ,&nbsp;Dana L. Casey","doi":"10.1016/j.clbc.2024.08.015","DOIUrl":"10.1016/j.clbc.2024.08.015","url":null,"abstract":"<div><h3>Purpose</h3><div>Understanding quality of life (QOL) implications of individual components of breast cancer treatment is important as systemic therapies continue to improve oncologic outcomes. We hypothesized that adjuvant radiation therapy does not significantly impact QOL domains in breast cancer patients undergoing chemotherapy.</div></div><div><h3>Methods</h3><div>Data was drawn from three prospective studies in women with localized breast cancer being treated with chemotherapy from March 2014 to December 2019. Patient-reported measures were collected at baseline (pretreatment) and post-treatment using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) measure, which consists of 5 subscales. Changes in mean QOL scores in patients who received radiotherapy were compared to those who did not using a one-sided noninferiority method. Statistical significance was determined below 0.05 to meet noninferiority.</div></div><div><h3>Results</h3><div>In a sample of 175 patients, 131 were treated with radiation and 44 had no radiation. The sample consisted mostly of stage I-II breast cancer (78%) with hormone receptor positive (59%) disease, receiving either neoadjuvant (36%) or adjuvant chemotherapy (64%). Mean change in QOL for the group treated with radiation compared to no radiation was noninferior with respect to Physical Well-Being (<em>P</em> = .0027), Social/Family Well-Being (<em>P</em> = .0002), Emotional Well-Being (<em>P</em> = .0203), FACIT-Fatigue Subscale (<em>P</em> = .0072), and the Total FACIT-F score (<em>P</em> = .0005); however, mean change in QOL did not meet noninferiority for Functional Well-Being (<em>P</em> = .0594).</div></div><div><h3>Conclusion</h3><div>Patient-reported QOL from baseline to post-treatment, using the Total FACIT-F score, was noninferior in patients treated with versus without radiation therapy. This finding, in addition to individualized QOL subscales, provides important information in the informed decision-making process when discussing the effects of locoregional radiation on QOL in localized breast cancer patients treated with chemotherapy.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e86-e93"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}